T1	Participants 11 167	children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study
T2	Participants 168 176	CCG-945.
T3	Participants 258 510	children who were treated with chemotherapy and radiotherapy on the Children's Cancer Group (CCG) high-grade glioma protocol (CCG-945) who were diagnosed with low-grade gliomas on post hoc central pathologic review and to identify clinical and biologic
T4	Participants 511 545	features associated with prognosis
T5	Participants 578 666	250 children with institutionally classified high-grade gliomas were enrolled on CCG-945
T6	Participants 668 990	Patients older than 24 months with intracranial lesions were assigned randomly to receive either lomustine, vincristine, and prednisone (control regimen) or the 8-drugs-in-1-day regimen (experimental regimen); younger patients and those with primary spinal cord tumors were assigned nonrandomly to the experimental regimen
T7	Participants 1172 1257	42 males and 28 females (median age, 7.7 years) with a median follow-up of 10.4 years
T8	Participants 555 576	Between 1985 and 1991
T9	Participants 1071 1143	low-grade glioma in 70 patients, who were the focus of the current study
